Christopher Hite

Director; EVP & Chairman, Partnering; EVP & Vice Chairman · 5 filings · Latest: Jun 23, 2026

Kailera Therapeutics, Inc.

Royalty Pharma plc

Vera Therapeutics, Inc.

Ticker	Owner	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Filing
RPRX	Christopher Hite	EVP & Chairman, Partnering	Jun 23, 2026	Sale	$54.40	150,000	$8.2M	559,399	Jun 25 9:11 PM
RPRX	Christopher Hite	—	Jun 23, 2026	Proposed Sale	$55.35	30,000	$1.7M	—	Jun 23 8:48 PM